BioCentury
ARTICLE | Financial News

BeiGene sets IPO terms

January 21, 2016 1:51 AM UTC

Cancer company BeiGene Ltd. (Beijing, China) set terms for its IPO on NASDAQ and now hopes to sell 5.5 million ADSs at $22-$24. At $23, it would raise $126.5 million and be valued at $685.9 million. Goldman Sachs, Morgan Stanley, Cowen and Baird are underwriters.

BeiGene is conducting the dose-expansion phase of a Phase I study of BGB-3111 to treat advanced B cell malignancies. It presented data from the study last month at the American Society of Hematology meeting in Orlando. BGB-3111 is a highly selective Bruton's tyrosine kinase inhibitor (see BioCentury Extra, Dec. 8, 2015). ...